Nedocromil is a pyrano quinoline used to treat allergic conjunctivitis. A pyranoquinolone derivative that inhibits activation of inflammatory cells which are associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets.
- Mechanism
- Curator reviewed
Nedocromil has been shown to inhibit the in vitro activation of, and mediator release from, a variety of inflammatory cell types associated with asthma, including eosinophils, neutrophils, macrophages, mast cells, monocytes, and platelets. Nedocromil inhibits activation and release of inflammatory mediators such as histamine, prostaglandin D2 and leukotrienes c4 from different types of cells in the lumen and mucosa of the bronchial tree. These mediators are derived from arachidonic acid metabolism through the lipoxygenase and cyclo-oxygenase pathways. The mechanism of action of nedocromil may be due partly to inhibition of axon reflexes and release of sensory neuropeptides, such as substance P, neurokinin A, and calcitonin-geneñrelated peptides. The result is inhibition of bradykinin-induced bronchoconstriction. Nedocromil does not posess any bronchodilator, antihistamine, or corticosteroid activity.
- Primary indication
- For the treatment of mild to moderate asthmaCurator reviewed · 3 structured indications
- Formula / weight
- C19H17NO7 · 371.3408 g/mol (avg)
- First approval
- Canada, 1997 · United States, 1992
- Code names
- FPL 59002
- Brand names
Resolves to
RQTOOFIXOKYGAN-UHFFFAOYSA-NSMILESCCCC1=C2N(CC)C(=CC(=O)C2=CC2=C1OC(=CC2=O)C(O)=O)C(O)=OWhat you can answer from here — as of October 01, 2026
Which drugs share a target with Nedocromil, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account